40004-08-8

Basic information

• Product Name: 1-(ETHOXYCARBONYLMETHYL)PIPERAZINE
• Synonyms: AKOS BC-0535;AKOS BBS-00006885;1-(ETHOXYCARBONYLMETHYL)PIPERAZINE;2-(PIPERAZIN-1-YL)-ACETIC ACID ETHYL ESTER;ETHYL 2-(PIPERAZIN-1-YL)ACETATE;ETHYL PIPERAZIN-1-YLACETATE;ETHYL PIPERAZINOACETATE;ETHYL 1-PIPERAZINEACETATE
• CAS NO: 40004-08-8
• Molecular Formula: C₈H₁₆N₂O₂
• Molecular Weight: 172.22
• EINECS: 254-745-3
• Product Categories: PIPERIDINE
• Mol File: 40004-08-8.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 127°C 13mm
• Flash Point: 127°C/13mm
• Appearance: /
• Density: 1.048 g/mL at 20 °C(lit.)
• Vapor Pressure: 0.0193mmHg at 25°C
• Refractive Index: n20/D 1.472
• Storage Temp.: ?20°C
• Solubility: Chloroform, Methanol
• PKA: 8.96±0.10(Predicted)
• Water Solubility: Soluble in water, chloroform, and methanol.
• Sensitive: Air Sensitive
• BRN: 743260
• CAS DataBase Reference: 1-(ETHOXYCARBONYLMETHYL)PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(ETHOXYCARBONYLMETHYL)PIPERAZINE(40004-08-8)
• EPA Substance Registry System: 1-(ETHOXYCARBONYLMETHYL)PIPERAZINE(40004-08-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: 8
• Hazardous Substances Data: 40004-08-8(Hazardous Substances Data)

Usage

Chemical Properties

1-(ETHOXYCARBONYLMETHYL)PIPERAZINE is Clear Thick Oil

Uses

Different sources of media describe the Uses of 40004-08-8 differently. You can refer to the following data:
1. 1-(ETHOXYCARBONYLMETHYL)PIPERAZINE is used in the preparation of aralkylpiperazine- and aryl-substituted hydrazines, particularly benzylpiperazineacetyl hydrazones of hydroxyaryl aldehydes, as selecti ve inducers of apoptosis and activators of procaspases for use as anticancer agents.
2. N-(Ethoxycarbonylmethyl)piperazine is used in the preparation of aralkylpiperazine- and aryl-substituted hydrazines, particularly benzylpiperazineacetyl hydrazones of hydroxyaryl aldehydes, as selective inducers of apoptosis and activators of procaspases for use as anticancer agents.

InChI:InChI=1/C8H16N2O2/c1-2-12-8(11)7-10-5-3-9-4-6-10/h9H,2-7H2,1H3

Upstream product

• 110-85-0 piperazine 
• 105-39-5 chloroacetic acid ethyl ester 
• 105-36-2 ethyl bromoacetate 
• 209667-59-4 tert-butyl 4-(2-ethoxy-2-oxoethyl)piperazine-1-carboxylic acid 

Downstream Products

• 23173-76-4 ethyl 2-(4-benzylpiperazin-1-yl)acetate 
• 2387-23-7 1,3-Dicyclohexylurea 
• 336191-54-9 4-nitrophenyl 4-(2-ethoxy-2-oxoethyl)-1-piperazine carboxylate 
• 374776-44-0 4-(5-(4-(ethoxycarbonylmethyl)piperazinylsulfonyl)-2-n-propoxybenzamido)-1-methyl-3-n-propylpyrazole-5-carboxamide 
• 374776-43-9 4-(2-ethoxy-5-(4-(ethoxycarbonylmethyl)piperazinylsulfonyl)benzamido)-1-methyl-3-n-propylpyrazole-5-carboxamide 
• 89704-67-6 [4-(2-Phenylsulfanyl-ethyl)-piperazin-1-yl]-acetic acid ethyl ester 
• 102535-31-9 [4-(2-Methoxy-5-sulfamoyl-benzoyl)-piperazin-1-yl]-acetic acid ethyl ester 
• 24637-27-2 Piperazino-essigsaeure-hydrazid 
• 119929-87-2 1-benzyl-4-carboxymethylpiperazine 
• 24632-70-0 2-(4-benzylpiperazin-1-yl)acetohydrazide 
• 1075725-60-8 2-(4-benzylpiperazin-1-yl)-N'-(3,5-diallyl-2-hydroxybenzylidene)acetohydrazide 
• 1075725-61-9 N'-(3-allyl-2-hydroxybenzylidene)-2-(4-(pyridin-2-ylmethyl)piperazin-1-yl)acetohydrazide 
• 1075725-62-0 N'-(3-allyl-2-hydroxybenzylidene)-2-(4-(pyridin-3-ylmethyl)piperazin-1-yl)acetohydrazide 
• 1075725-63-1 N'-(3-allyl-2-hydroxybenzylidene)-2-(4-(pyridin-4-ylmethyl)piperazin-1-yl)acetohydrazide 

Relevant articles and documents

Fused ring compound, pharmaceutical composition containing fused ring compound, and preparation method and application of fused ring compound

The present invention relates to a fused ring compound as shown in Formula (I-A) or Formula (I-B) which is described in the specification, a pharmaceutical composition comprising the same, a preparation method and an application in the prevention or treatment of diseases or conditions associated with RET activity.

Tankyrase inhibitor

The invention belongs to the technical field of medicines and particularly relates to a tankyrase inhibitor represented by a general formula (I) shown in the description and pharmaceutically acceptable salts, esters, solvates or stereoisomers thereof, wherein R1, R2, R3, m, n, Z, L, Q, A, X1, X2 and Y are as defined in the description. The invention further relates to a preparation method for the compounds, pharmaceutical preparations and pharmaceutical compositions containing the compounds and application of the compound and the pharmaceutically acceptable salts, esters, solvates or stereoisomers thereof in preparation of drugs for treating and/or preventing tankyrase mediated cancers and related diseases.

Removal of metabolic liabilities enables development of derivatives of procaspase-activating compound 1 (PAC-1) with improved pharmacokinetics

Procaspase-activating compound 1 (PAC-1) is an o-hydroxy-N-acylhydrazone that induces apoptosis in cancer cells by chelation of labile inhibitory zinc from procaspase-3. PAC-1 has been assessed in a wide variety of cell culture experiments and in vivo models of cancer, with promising results, and a phase 1 clinical trial in cancer patients has been initiated (NCT02355535). For certain applications, however, the in vivo half-life of PAC-1 could be limiting. Thus, with the goal of developing a compound with enhanced metabolic stability, a series of PAC-1 analogues were designed containing modifications that systematically block sites of metabolic vulnerability. Evaluation of the library of compounds identified four potentially superior candidates with comparable anticancer activity in cell culture, enhanced metabolic stability in liver microsomes, and improved tolerability in mice. In head-to-head experiments with PAC-1, pharmacokinetic evaluation in mice demonstrated extended elimination half-lives and greater area under the curve values for each of the four compounds, suggesting them as promising candidates for further development.